[The Potential Use of Cannabidiol in the Therapy of Metabolic Syndrome]

Orv Hetil. 2012 Apr 1;153(13):499-504. doi: 10.1556/OH.2012.29308.
[Article in Hungarian]

Abstract

Cannabidiol, a cannabinoid and serotonin receptor antagonist, may alleviate hyperphagia without the side effects of rimonabant (for example depression and reduced insulin sensitivity). Similar to the peroxisome proliferator-activated receptor-gamma agonists, it may also help the differentation of adipocytes. Cannabidiol has an immunomodulating effect, as well, that helps lessen the progression of atherosclerosis induced by high glucose level. It may also be effective in fighting ischaemic diseases, the most harmful complications of metabolic syndrome. However, it can only be administered as an adjuvant therapy because of its low binding potency, and its inhibiting effect of cytochrome P450 enzymes should also be considered. Nevertheless, it may be beneficially used in adjuvant therapy because of its few side effects.

Publication types

  • Review

MeSH terms

  • Adipocytes / drug effects
  • Appetite Depressants / pharmacology*
  • Appetite Depressants / therapeutic use
  • Atherosclerosis / prevention & control
  • Cannabidiol / pharmacology*
  • Cannabidiol / therapeutic use
  • Cannabinoid Receptor Antagonists
  • Disease Progression
  • Humans
  • Hyperphagia / prevention & control*
  • Ischemia / prevention & control
  • Metabolic Syndrome / drug therapy*
  • Obesity / drug therapy*
  • PPAR gamma / agonists*
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Piperidines / chemistry
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / chemistry
  • Rimonabant

Substances

  • Appetite Depressants
  • Cannabinoid Receptor Antagonists
  • PPAR gamma
  • Piperidines
  • Pyrazoles
  • Cannabidiol
  • Rimonabant